Related Experiment Video
Updated: Feb 1, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision
1Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, ggoel.uky@gmail.com.
Abstract:
Colorectal cancer (CRC) is a major public health problem, both in the USA and globally. Over the past 20 years, significant advances have been made in the treatment of patients with metastatic CRC (mCRC). Recent efforts in the field of biomarkers have focused on the development of molecular diagnostics to define the subset of patients with mCRC that is likely to derive most benefit from anti-EGFR therapy. Herein, we review the recent advancements in molecular stratification of CRC and the role of current as well as emerging biomarkers in this disease. It is now clear that the presence of activating mutations in the KRAS and NRAS genes serves as reliable predictive markers for resistance to anti-EGFR therapy in mCRC. It is also clear that further improvements in the survival of mCRC patients will probably be made possible only with identification of new predictive molecular biomarkers and their evaluation using rational and innovative clinical trials. The recent advances in DNA sequencing technology and "omics"-based approaches have provided promising new strategies for the development of novel molecular biomarkers in this disease.
Insights
Molecular biomarkers like KRAS and NRAS mutations help predict treatment response in metastatic colorectal cancer (mCRC). Identifying new biomarkers through advanced sequencing and omics approaches is crucial for improving patient survival.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- Colorectal cancer (CRC) presents a significant global health challenge.
- Advances in treating metastatic CRC (mCRC) have been substantial over the last two decades.
- Biomarker development is key to personalizing anti-EGFR therapy for mCRC patients.
Purpose of the Study:
- To review recent progress in molecular stratification for CRC.
- To discuss the role of current and emerging biomarkers in mCRC treatment.
- To highlight the impact of genetic mutations on therapeutic outcomes.
Main Methods:
- Review of recent advancements in molecular diagnostics for CRC.
- Analysis of the predictive value of genetic mutations (e.g., KRAS, NRAS) in mCRC.
- Exploration of next-generation sequencing and omics-based strategies.
Main Results:
- Activating mutations in KRAS and NRAS genes are established predictors of resistance to anti-EGFR therapy in mCRC.
- Molecular stratification is essential for optimizing treatment selection.
- Advanced technologies offer new avenues for biomarker discovery.
Conclusions:
- KRAS and NRAS mutations are critical for guiding anti-EGFR therapy decisions in mCRC.
- Further survival improvements in mCRC necessitate the discovery and validation of novel predictive biomarkers.
- Innovative clinical trials and omics approaches are vital for future biomarker development.
More Related Videos
10:33Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
Published on: April 29, 2014
15:17Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Related Concept Videos
Dreaming
Lucid Dreaming
Studies have shown...
Uncertainty in Measurement: Accuracy and Precision
Microorganisms in Medicine and Therapeutics
Molecular Models
Accuracy and Precision